Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System. 2016

Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Pyrazinamide (PZA) is a key antituberculosis drug, yet no rapid susceptibility test is commercially available. PZA drug susceptibility testing (DST) was performed directly on sputum samples from 327 patients and compared with the indirect method by using the Bactec MGIT 960 system in the context of patient screening for participation in a drug trial. Compared to standard indirect PZA DST, direct DST was successful in only 59% of cases, but results obtained were highly accurate and available faster. Agreement between the direct and indirect methods varied from 90 to 100% in each laboratory. The median times for obtaining PZA results from the time when the specimen was collected ranged from 11 to 16 days for the direct test and 18 to 95 days for the indirect test across laboratories. The direct method is accurate and reproducible across laboratories. It can be expected to accelerate results in >50% of cases, but it cannot replace indirect DST for PZA. Phenotypic methods remain the gold standard for DST in drug trials. If future studies can optimize the method to decrease the number of uninterpretable results, direct MGIT DST could be the new phenotypic DST standard for clinical trials, providing more rapid detection of resistance to new drugs in experimental regimens.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D011718 Pyrazinamide A pyrazine that is used therapeutically as an antitubercular agent. Tisamid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D013183 Sputum Material coughed up from the lungs and expectorated via the mouth. It contains MUCUS, cellular debris, and microorganisms. It may also contain blood or pus. Sputum, Induced,Induced Sputum,Induced Sputums,Sputums,Sputums, Induced
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face

Related Publications

Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
May 2002, Journal of clinical microbiology,
Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
January 2019, International journal of mycobacteriology,
Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
January 2010, Journal of clinical microbiology,
Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
October 2003, Journal of microbiological methods,
Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
December 2017, Journal of clinical microbiology,
Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
December 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
July 2010, The Indian journal of medical research,
Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
November 2009, Journal of clinical microbiology,
Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
October 2012, Journal of microbiological methods,
Anne-Marie Demers, and Amour Venter, and Sven O Friedrich, and Gabriel Rojas-Ponce, and Daniel Mapamba, and Levan Jugheli, and Mohammed Sasamalo, and Deepak Almeida, and Afton Dorasamy, and Ute Jentsch, and Mara Gibson, and Daniel Everitt, and Kathleen D Eisenach, and Andreas H Diacon
January 2014, PloS one,
Copied contents to your clipboard!